Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:alternativeName |
Lonafarnib
SCH-66336 |
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:United_States
gptkb:Hutchinson-Gilford_progeria_syndrome |
| gptkbp:ATCCode |
L01XX62
|
| gptkbp:CASNumber |
gptkb:193275-84-2
|
| gptkbp:clinicalTrialPhase |
yes
|
| gptkbp:developedBy |
gptkb:Schering-Plough
|
| gptkbp:hasInChIKey |
QXJYYWQWQZJZDG-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C27H31ClN4O4
|
| gptkbp:hasSMILES |
CC1=CC(=O)N(C)C(=C1)C2=CC=CC=C2ClC3=NC=CC(=N3)NC(=O)C4CCN(CC4)C(=O)C
|
| gptkbp:hasUNII |
7R6XIC43EI
|
| https://www.w3.org/2000/01/rdf-schema#label |
SCH66336
|
| gptkbp:legalStatus |
patented
prescription only (US) |
| gptkbp:mechanismOfAction |
farnesyltransferase inhibitor
|
| gptkbp:molecularWeight |
511.01 g/mol
|
| gptkbp:PubChem_CID |
151124
CHEMBL190837 DB04932 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:usedFor |
gptkb:progeria
gptkb:Hutchinson-Gilford_progeria_syndrome cancer (investigational) |
| gptkbp:bfsParent |
gptkb:lonafarnib
|
| gptkbp:bfsLayer |
7
|